18F-Fluoromisonidazole in tumor hypoxia imaging

Zuoyu Xu, Xiao-Feng Li, Hongyan Zou, Xilin Sun and Baozhong Shen _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:94969-94979. https://doi.org/10.18632/oncotarget.21662

Metrics: PDF 772 views  |   HTML 1606 views  |   ?  


Zuoyu Xu1,2, Xiao-Feng Li1,2, Hongyan Zou1, Xilin Sun1,2 and Baozhong Shen1,2

1Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin, Heilongjiang, China

2TOF-PET/CT/MR Center, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, China

Correspondence to:

Baozhong Shen, email: shenbz@ems.hrbmu.edu.cn

Xilin Sun, email: sunxl@ems.hrbmu.edu.cn

Keywords: hypoxia, 18F-Fluoromisonidazole, PET, tumor

Received: June 28, 2017     Accepted: September 21, 2017     Published: October 07, 2017


Hypoxia is a common feature of solid tumors that is closely associated with radiotherapy and chemotherapy resistance, metastasis and tumors prognosis. Thus, it is important to assess hypoxia in tumors for estimating prognosis and selecting appropriate treatment procedures. 18F-Fluoromisonidazole positron emission tomography (18F-FMISO PET) has been widely used to visualize tumor hypoxia in a comprehensive and noninvasive way, both in the clinical and preclinical settings. Here we review the concept, mechanisms and detection methods of tumor hypoxia. Furthermore, we discuss the correlation between 18F-FMISO PET and other detection methods, current applications of 18F-FMISO PET and the development prospects of this imaging technology.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21662